[Comparison of induction protocols for VEN+AZA and HAG+AZA in single-center elderly acute myeloid leukemia]

Zhonghua Xue Ye Xue Za Zhi. 2023 Sep 14;44(9):767-769. doi: 10.3760/cma.j.issn.0253-2727.2023.09.011.

[Article in Chinese]

Authors

X X Lu¹, L Y Yuan², K Q Liu³, Q Q Zhang¹, X Wang¹, X S Jiang¹, J S Zhang¹, X L Zhao¹

Affiliations

¹ Department of Hematology, Oncology Center, Tianjin Union Medical Center of Nankai University, Tianjin 300121, China.
² School of Medicine, Nankai University, Tianjin 300071, China.
³ Institute of Hematology & Blood Disease, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.

PMID: 38049322
PMCID: PMC10630569
DOI: 10.3760/cma.j.issn.0253-2727.2023.09.011

No abstract available

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols
Azacitidine / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Humans
Leukemia, Myeloid, Acute* / drug therapy
Treatment Outcome

Substances

Azacitidine
Bridged Bicyclo Compounds, Heterocyclic

Grants and funding

基金项目：天津科技计划项目（21JCYBJC00290）；天津重点医学专业（专业）建设项目（TJYXZDXK-053B）；天津市人民医院院级课题（2020YJ012、2021YJ014）